Krystal Biotech, Inc. (KRYS) shareholders
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (14.94%) | 4,292,881 | 14.94% | 13G (passive) amendment | Nov 12, 2024 |
| BlackRock, Inc. | 3,427,645 | 11.60% | 13G (passive) amendment | Sep 30, 2026 |
| Krish S. Krishnan Joint filing with Suma M. Krishnan (11.50%) | 3,388,283 | 11.50% | 13G (passive) amendment | Mar 31, 2026 |
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (9.10%) | 2,565,555 | 9.10% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KRYS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,418,197 | 14.93% | $1.64B | +44,210 | 0.07% |
| BlackRock, Inc. | 4,181,432 | 14.13% | $1.55B | +240,976 | 0.02% |
| Avoro Capital Advisors LLC | 2,888,888 | 9.76% | $1.07B | – | 9.64% |
| Vanguard Portfolio Management LLC | 1,574,905 | 5.32% | $585.34M | +118,178 | 0.03% |
| State Street Corp | 1,351,158 | 4.56% | $502.20M | +36,724 | 0.01% |
| Vanguard Capital Management LLC | 1,240,567 | 4.19% | $461.08M | +75,243 | 0.01% |
| Soleus Capital Management, L.P. | 939,254 | 3.17% | $349.09M | −213,833 | 12.03% |
| Capital World Investors | 777,843 | 2.63% | $289.10M | −46,877 | 0.03% |
| Vestor Capital, LLC | 700,914 | 2.37% | $78.19M | +700,714 | 4.88% |
| Geode Capital Management, LLC | 698,993 | 2.36% | $259.84M | +55,018 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 687,400 | 2.32% | $255.49M | +202,326 | 0.03% |
| Hood River Capital Management LLC | 663,375 | 2.24% | $246.56M | +43,789 | 1.79% |
| Redmile Group, LLC | 632,005 | 2.14% | $234.90M | −41,500 | 15.77% |
| William Blair Investment Management, LLC | 570,153 | 1.93% | $211.91M | +162,975 | 0.64% |
| Frazier Life Sciences Management, L.P. | 481,307 | 1.63% | $178.89M | – | 3.90% |
| Dimensional Fund Advisors LP | 476,038 | 1.61% | $176.94M | +7,048 | 0.03% |
| First Trust Advisors LP | 324,900 | 1.10% | $120.76M | −25,621 | 0.07% |
| Invesco Ltd. | 324,755 | 1.10% | $120.70M | +73,382 | 0.01% |
| Goldman Sachs Group Inc | 298,841 | 1.01% | $111.07M | +83,892 | 0.01% |
| Northern Trust Corp | 283,784 | 0.96% | $105.47M | +31,321 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 422 | 30M | 100.0% | 94 / 176 | 109 / 36 | 3M | 1M |
| Q1 2026 | 368 | 28M | 95.9% | 76 / 138 | 105 / 36 | 4M | 2M |
| Q4 2025 | 334 | 28M | 96.2% | 82 / 112 | 104 / 27 | 2M | 2M |
| Q3 2025 | 284 | 28M | 95.1% | 46 / 107 | 86 / 32 | 2M | 2M |
| Q2 2025 | 275 | 28M | 93.4% | 42 / 101 | 97 / 63 | 3M | 3M |
| Q1 2025 | 299 | 28M | 93.5% | 64 / 89 | 112 / 27 | 2M | 2M |
| Q4 2024 | 264 | 28M | 93.8% | 37 / 94 | 98 / 52 | 1M | 2M |
| Q3 2024 | 283 | 28M | 96.0% | 55 / 106 | 89 / 15 | 6M | 2M |
| Q2 2024 | 245 | 29M | 98.3% | 52 / 99 | 72 / 40 | 5M | 2M |
| Q1 2024 | 234 | 26M | 89.0% | 66 / 63 | 82 / 25 | 4M | 3M |
| Q4 2023 | 194 | 26M | 86.4% | 29 / 73 | 65 / 20 | 4M | 3M |
| Q3 2023 | 188 | 24M | 82.7% | 21 / 89 | 52 / 14 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
385 funds held KRYS in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of KRYS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 1,802,622 | 6.09% | $557.06M | 10.58% | May 31, 2026 |
| iShares Core S&P Small-Cap ETF | 1,580,327 | 5.34% | $587.36M | 0.53% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 889,548 | 3.01% | $330.62M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 788,525 | 2.66% | $243.68M | 0.25% | May 31, 2026 |
| SMALLCAP World Fund Inc | 752,244 | 2.54% | $279.59M | 0.30% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 670,870 | 2.27% | $249.34M | 0.30% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 642,490 | 2.17% | $238.79M | 0.13% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 370,503 | 1.25% | $137.70M | 0.29% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 329,780 | 1.11% | $122.57M | 1.84% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 318,741 | 1.08% | $118.47M | 1.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 301,179 | 1.02% | $111.94M | 0.11% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 293,036 | 0.99% | $108.91M | 3.87% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 285,631 | 0.97% | $97.43M | 0.29% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 241,279 | 0.82% | $89.68M | 0.58% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 240,760 | 0.81% | $89.48M | 0.53% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Krish S. Krishnan | President and CEO, Director, 10% owner | 1,567,863 | 5.30% | Sep 4, 2026 |
| Suma Krishnan | President, R&D, Director, 10% owner | 1,512,362 | 5.11% | Sep 4, 2026 |
| John Charles Thomas | EVP, General Counsel | 1,000 | 0.00% | Jun 26, 2026 |
| Laurent Louis Jean Goux | EVP, Head of International | 919 | 0.00% | Mar 6, 2026 |
| Kathryn Romano | Chief Accounting Officer | 22,366 | 0.08% | Mar 3, 2026 |
| Dino A. Rossi | Director | 46,500 | 0.16% | Nov 13, 2026 |
| Daniel Janney | Director | 76,409 | 0.26% | Sep 16, 2026 |
| Catherine Mazzacco | Director | – | – | Sep 16, 2026 |
| Julian S. Gangolli | Director | 20,000 | 0.07% | Sep 16, 2026 |
| Christopher Mason | Director | – | – | Sep 16, 2026 |
| Everett Rand Sutherland | Director | – | – | Sep 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dino A. Rossi Director | Nov 12, 2026 | Gift | −3,500 | – | – | 46,500 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,267 | $356.37 | $1.16M | 1,321,352 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −399 | $366.56 | $146.26K | 1,302,145 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −826 | $365.41 | $301.83K | 1,302,544 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,329 | $364.48 | $484.39K | 1,303,370 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −520 | $354.54 | $184.36K | 1,326,625 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,006 | $355.57 | $713.27K | 1,324,619 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −565 | $363.34 | $205.29K | 1,304,699 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,962 | $357.57 | $1.42M | 1,317,390 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,180 | $358.42 | $1.14M | 1,314,210 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,392 | $359.39 | $1.22M | 1,310,818 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,320 | $360.47 | $836.29K | 1,308,498 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,242 | $361.61 | $449.12K | 1,307,256 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,992 | $362.65 | $722.40K | 1,305,264 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −573 | $363.34 | $208.19K | 1,350,153 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,010 | $362.65 | $728.93K | 1,350,726 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,214 | $361.61 | $438.99K | 1,352,736 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,266 | $360.46 | $816.80K | 1,353,950 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,357 | $359.39 | $1.21M | 1,356,216 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,143 | $358.42 | $1.13M | 1,359,573 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,981 | $357.57 | $1.42M | 1,362,716 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,297 | $356.37 | $1.17M | 1,366,697 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,029 | $355.57 | $721.45K | 1,369,994 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −520 | $354.54 | $184.36K | 1,372,023 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −405 | $366.56 | $148.46K | 1,347,543 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −847 | $365.42 | $309.51K | 1,347,948 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,358 | $364.48 | $494.96K | 1,348,795 |
| Dino A. Rossi Director | Aug 14, 2026 | Gift | −3,691 | – | – | 75,000 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −341 | $325.60 | $111.03K | 74,659 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −2,287 | $326.60 | $746.93K | 72,372 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −5,226 | $327.39 | $1.71M | 67,146 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −1,687 | $328.52 | $554.21K | 65,459 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −7,428 | $329.60 | $2.45M | 58,031 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −4,896 | $330.36 | $1.62M | 53,135 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −3,095 | $331.43 | $1.03M | 50,040 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −40 | $333.23 | $13.33K | 50,000 |
| John Charles Thomas EVP, General Counsel | Jun 25, 2026 | Option exercise | +1,000 | $179.25 | $179.25K | 1,000 |
| John Charles Thomas EVP, General Counsel | Jun 25, 2026 | Sale(10b5-1 plan) | −1,000 | $347.27 | $347.27K | 0 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −1,348 | $307.09 | $413.96K | 1,399,767 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,039 | $310.94 | $634.01K | 1,378,395 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,801 | $309.95 | $868.17K | 1,380,434 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −3,803 | $308.89 | $1.17M | 1,383,235 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −12,729 | $307.81 | $3.92M | 1,387,038 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −240 | $311.65 | $74.80K | 1,378,155 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −480 | $305.87 | $146.82K | 1,401,115 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −400 | $304.89 | $121.96K | 1,401,595 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −247 | $303.17 | $74.88K | 1,401,995 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −593 | $302.25 | $179.23K | 1,402,242 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −320 | $300.75 | $96.24K | 1,402,835 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −11,461 | $307.68 | $3.53M | 1,461,523 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −589 | $306.33 | $180.43K | 1,472,984 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −544 | $304.81 | $165.82K | 1,473,573 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −4,830 | $308.47 | $1.49M | 1,456,693 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,784 | $309.49 | $861.62K | 1,453,909 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,652 | $310.43 | $823.26K | 1,451,257 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −964 | $311.36 | $300.15K | 1,450,293 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −40 | $312.23 | $12.49K | 1,450,253 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −176 | $303.17 | $53.36K | 1,474,117 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −640 | $302.24 | $193.43K | 1,474,293 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −320 | $300.75 | $96.24K | 1,474,933 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Krystal Biotech's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,408 shares on Sep 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Suma Krishnan Director, Officer, 10% Stockholder | Sep 4, 2026 | 25,000 | $9.29M | Sep 4, 2026 | Founders Shares |
| Krish S. Krishnan Director, Officer, 10% Stockholder | Sep 4, 2026 | 25,000 | $9.29M | Sep 4, 2026 | Founders Shares |
| Dino A. Rossi Director | Aug 14, 2026 | 25,000 | $8.31M | Aug 14, 2026 | Acquired from public market |
| John Charles Thomas Officer | Jun 25, 2026 | 1,000 | $347.27K | Jun 25, 2026 | Stock Option Exercise |
| Krish S. Krishnan Director, Officer, 10% Stockholder | Jun 4, 2026 | 25,000 | $7.55M | Jun 4, 2026 | Founders Shares |
| Suma Krishnan Director, Officer, 10% Stockholder | Jun 4, 2026 | 25,000 | $7.55M | Jun 4, 2026 | Founders Shares |
| John Charles Thomas Officer | May 26, 2026 | 642 | $193.90K | May 26, 2026 | Restricted Stock Vesting |
| Suma Krishnan Director, Officer, 10% Stockholder | Mar 4, 2026 | 25,000 | $6.60M | Mar 4, 2026 | Founders Shares |
| Krish S. Krishnan Director, Officer, 10% Stockholder | Mar 4, 2026 | 25,000 | $6.60M | Mar 4, 2026 | Founders Shares |
| Kathryn Romano Officer | Mar 2, 2026 | 750 | $200.70K | Mar 2, 2026 | Restricted Stock Vesting |
| Daniel Janney Director | Feb 27, 2026 | 11,803 | $3.25M | Feb 27, 2026 | Private Placement |
| Daniel Janney Director | Feb 26, 2026 | 7,741 | $2.13M | Feb 26, 2026 | Private Placement |
| Daniel Janney Director | Feb 25, 2026 | 700 | $192.50K | Feb 25, 2026 | Private Placement |
| Daniel Janney Director | Feb 24, 2026 | 13,825 | $3.71M | Feb 24, 2026 | Private Placement |
| Daniel Janney Director | Feb 24, 2026 | 37,895 | $10.11M | Feb 24, 2026 | Option Granted 11/10/2016 |
Congress trades
1 trade in Krystal Biotech reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Dec 12, 2022 | $1K–15K | Jan 20, 2023 |
See a number that looks wrong?